Abstract: A cell implant matrix has a connective porosity of more than 80% and consists mainly of a mixture of bioresorbable polymers, wherein the matrix has disk-shape and wherein a surface layer on one side of the disk has less than 20% of the average pore density of the other sides. The matrix is manufactured by providing a bioresorbable polymer layer; stratifying, onto the polymer layer, a mixture of a water-soluble solid, at least two polymers differing with respect to their resorption rates, and a solvent for one of the polymers; evaporating the solvent optionally followed by compacting the mixture; and watering the compacted body to remove the salt.

Abstract: A porous implant matrix consists mainly of a mixture of polymers which are differently rapidly degradable, wherein nominal resorption times of two of the components of the mixture, each accounting for at least 10% of the mixture, differ by a factor of at least 5. The porous implant matrix is manufactured from a mixture of the at least two differently rapidly degradable polymers, wherein particles of both polymers are mixed with particles of a water-soluble solid and a solvent for one of the polymers, and after evaporating the solvent is optionally compacted, and the solid is removed by watering.

Abstract: A method for coating a hollow body on its inner surface comprises pre-coating the inner surface with a reactive gas plasma (PECVD), and follow-up-coating the pre-coated surface with a reactive gas component without plasma action (CVD). The resulting hollow body is used for temporarily accommodating bodily liquids, in particular blood, or cell suspensions, due to its hydrophilizing PECVD/CVD-coating on its inner surface.

Abstract: The invention relates to a method for hydrophilizing surfaces of polymer workpieces. The method has a step (a) of pretreating the workpiece surfaces in a high-frequency gas plasma which is produced on the basis of an inert gas in order to clean and activate the workpiece surfaces; a step (b) of precoating the pretreated workpiece surfaces with polyacrylic acid using a high-frequency gas plasma made of a gas mixture, said gas mixture being composed of an inert gas and a first gas made of biocompatible, polymerizable carboxy group-containing monomers; and a step (c) of subsequently coating the precoated workpiece surfaces using a second gas substantially containing acrylic acid monomers.

Abstract: A pharmaceutical composition for use in a method for liver regeneration or for enhancement of the liver performance comprises the vitamins B6, B9, and B12 in the daily doses: B6 not less than 4 mg, optionally not more than 500 mg; B9 not less than 0.6 mg, optionally not more than 15 mg; B12 not less than 0.008 mg, optionally not more than 4 mg.

Abstract: A silicone contact lens has a radial cross-section of the inner face, the rim portion contour of which is convex between a point of inflection and the outer edge. For its manufacture, a silicone precursor is brought between a female and a male mold and is polymerized, and the polymerized contact lens is released from the mold by means of a liquid swelling same.

Abstract: A hydrophilizingly coated silicone contact lens has a radial cross-section of the inner face (1), the rim portion contour of which is convex (7) between a point of inflection (6) and the outer edge. For its manufacture, a silicone precursor is brought between a female and a male mold and is polymerized, and the polymerized contact lens is released from the mold by means of a liquid swelling same and is completed after a PECVD/CVD-coating without edge cutting.

Abstract: A cell implant matrix has a connective porosity of more than 80% and consists mainly of a mixture of bioresorbable polymers, wherein the matrix has disk-shape and wherein a surface layer on one side of the disk has less than 20% of the average pore density of the other sides. The matrix is manufactured by providing a bioresorbable polymer layer; stratifying, onto the polymer layer, a mixture of a water-soluble solid, at least two polymers differing with respect to their resorption rates, and a solvent for one of the polymers; evaporating the solvent optionally followed by compacting the mixture; and watering the compacted body to remove the salt.

Abstract: A porous implant matrix consists mainly of a mixture of polymers which are differently rapidly degradable, wherein nominal resorption times of two of the components of the mixture, each accounting for at least 10% of the mixture, differ by a factor of at least 5. The porous implant matrix is manufactured from a mixture of the at least two differently rapidly degradable polymers, wherein particles of both polymers are mixed with particles of a water-soluble solid and a solvent for one of the polymers, and after evaporating the solvent is optionally compacted, and the solid is removed by watering.

Abstract: A silicone contact lens has a radial cross-section of the inner face, the rim portion contour of which is convex between a point of inflection and the outer edge. For its manufacture, a silicone precursor is brought between a female and a male mold and is polymerized, and the polymerized contact lens is released from the mold by means of a liquid swelling same.

Abstract: The invention relates to a method for hydrophilizing surfaces of polymer workpieces. The method has a step (a) of pretreating the workpiece surfaces in a high-frequency gas plasma which is produced on the basis of an inert gas in order to clean and activate the workpiece surfaces; a step (b) of precoating the pretreated workpiece surfaces with polyacrylic acid using a high-frequency gas plasma made of a gas mixture, said gas mixture being composed of an inert gas and a first gas made of biocompatible, polymerizable carboxy group-containing monomers; and a step (c) of subsequently coating the precoated workpiece surfaces using a second gas substantially containing acrylic acid monomers.

Abstract: The invention relates to agents containing a folic acid, vitamin B6 and vitamin B12 and to the use thereof in hyperhomocystenemia for controlling homocysteine levels. The inventive agents are particularly suitable for preventive and acute treatment of vascular diseases of pregnant women and neurodegenerative diseases and are particularly advantageous in cases of hyperhomocysteinemia whose treatment with homocysteine level reducing agents causes secondary effects. Pharmaceutical agents and food supplements comprising the corresponding active substance combination, agents in the form of commercial packages containing corresponding combination preparations or monopreparations for a combined application are, in particular, also disclosed.

Abstract: The invention relates to porous matrices based on a biologically compatible polymer or polymer mixture, to a cell implantation that is established on said matrices and to additional cell implantation based on cell mixtures of hepatocytes and islets of Langerhans. The invention also relates to a method for producing porous matrices, to matrices obtained according to said method and to a special method for obtaining cells for the inoculation of an implantable matrix.

Abstract: The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12, and to the use thereof in hyperhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous in cases where the homocysteine levels to be controlled are found in an individual suffering from renal failure or being treated with immune suppressors. The invention particularly relates to pharmaceutical agents and food supplements comprising a corresponding active ingredient combination and to agents in the form of commercial packages containing corresponding combination preparations or monopreparations for the combined use.

Abstract: The invention relates to a method for testing one or several substances. According to said method, a tissue equivalent is cultivated, the substance/s is/are made to affect the tissue equivalent, and it is determined whether the effect of the substance/s has resulted in a modification of the tissue equivalent and/or the substance/s. The tissue equivalent comprises at least one cell and a porous matrix based on a biologically compatible polymer or polymer mixture. The matrix is provided with pores having a maximum size of 150 ?m as well as pores having a minimum size of 300 ?m while the degree of porosity is 93 to 98 percent.

Abstract: The invention relates to porous matrices based on a biologically compatible polymer or polymer mixture, to a cell implantation that is established on said matrices and to additional cell implantation based on cell mixtures of hepatocytes and islets of Langerhans. The invention also relates to a method for producing porous matrices, to matrices obtained according to said method and to a special method for obtaining cells for the inoculation of an implantable matrix.

Abstract: The invention relates to porous matrices based on a biologically compatible polymer or polymer mixture, to a cell implantation that is established on said matrices and to additional cell implantation based on cell mixtures of hepatocytes and islets of Langerhans. The invention also relates to a method for producing porous matrices, to matrices obtained according to said method and to a special method for obtaining cells for the inoculation of an implantable matrix.

Abstract: (EN) The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12. and to the use thereof in hyperhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous in cases where the homocysteine levels to be controlled are found in an individual suffering from renal failure or being treated with immune suppressors. The invention particularly relates to pharmaceutical agents and food supplements comprising a corresponding active ingredient combination and to agents in the form of commercial packages containing corresponding combination preparations or monopreparations for the combined use.

Abstract: The invention relates to a method for testing one or several substances. According to said method, a tissue equivalent is cultivated, the substance/s is/are made to affect the tissue equivalent, and it is determined whether the effect of the substance/s has resulted in a modification of the tissue equivalent and/or the substance/s. The tissue equivalent comprises at least one cell and a porous matrix based on a biologically compatible polymer or polymer mixture. The matrix is provided with pores having a maximum size of 150 ?m as well as pores having a minimum size of 300 ?m while the degree of porosity is 93 to 98 percent.

Abstract: The invention relates to agents containing a folic acid, vitamin B6 and vitamin B12 and to the use thereof in hyperhomocystenemia for controlling homocysteine levels. The inventive agents are particularly suitable for preventive and acute treatment of vascular diseases of pregnant women and neurodegenerative diseases and are particularly advantageous in cases of hyperhomocysteinemia whose treatment with homocysteine level reducing agents causes secondary effects. Pharmaceutical agents and food supplements comprising the corresponding active substance combination, agents in the form of commercial packages containing corresponding combination preparations or monopreparations for a combined application are, in particular, also disclosed.